TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily pill Juvmo, known as tavapadon in clinical trials, on Sept. 25, 2026, for treating Parkinson’s symptoms. It can be used alone in early disease or added to other medicines in later stages; AbbVie expects U.S. availability in October 2026. The trials reported improvements in motor symptoms, but they were not long enough to determine whether Juvmo affects the risk of impulse-control problems.
The U.S. Food and Drug Administration approved AbbVie’s once-daily Parkinson’s pill Juvmo on Sept. 25 for treating motor symptoms, allowing it to be prescribed alone in early disease or alongside existing medicines in later stages. The drug, called tavapadon during clinical trials, offers another treatment option for people whose symptoms include tremors, stiffness and slowed movement; AbbVie expects it to be available in the United States in October 2026.
Juvmo’s approval covers two uses: as a standalone treatment for early Parkinson’s and as an add-on to existing medication in later stages. In the add-on setting, the aim is to extend “on time,” when medication is controlling symptoms, and reduce “off time,” when its effect has worn away. The report does not specify the approved dose or provide full prescribing instructions.
AbbVie tested tavapadon in three randomized, placebo-controlled Phase 3 trials, each lasting 26 weeks and involving more than 1,300 participants in total. The two trials of the drug as a standalone treatment found improvements in motor symptoms, with reported side effects that included nausea and headache. In the third trial, which tested it as an add-on, participants had longer on time and reduced off time, according to the report.
Existing Parkinson’s medicines can require doses several times a day and may cause unwanted effects, including dyskinesia, or uncontrolled movements, and impulse-control problems. The source report says some people discontinue medication within the first year, but does not give a study or figure for that claim. Juvmo’s once-daily schedule and different receptor targets distinguish it from commonly used dopamine agonists; the approval does not establish that it is free of these or other side effects.
A New Option for Motor Symptoms
The approval adds a once-daily option to treatment choices for a disease that affects movement and often requires ongoing medication management. Its two approved uses may let clinicians consider the same medicine at different stages: alone for early symptoms or alongside other treatment when its effects do not last long enough. That flexibility could matter for patients and clinicians weighing symptom control, schedules and tolerability.
The reported trial results point to potential benefits for motor symptoms and time spent with medication working. However, the available information does not establish how Juvmo compares with other treatments, how benefits and risks change over longer periods, or which patients are most likely to benefit. Approval creates an additional option, not a guarantee of better outcomes for every person with Parkinson’s.
Parkinson's medication pill organizer
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Juvmo Targets Dopamine
Parkinson’s disease involves the loss of neurons that produce dopamine, a chemical involved in movement. Many established dopamine agonists mimic dopamine by activating D2 and D3 receptors. Juvmo instead targets D1 and D5 receptors, activating different dopamine pathways, according to the source report.
That mechanism provides a scientific rationale for studying tavapadon as an alternative, but a different target does not by itself prove that a medicine causes fewer side effects in everyday use. The cited clinical program lasted 26 weeks per trial. That duration allowed researchers to measure symptoms and common reported effects during the trials, but it was not long enough to answer every question about longer-term safety.
“It’s not a huge game-changer, but definitely a nice additional tool to have.”
— Dr. Bryan Ho, Tufts Medical Center neurologist and director of its Movement Disorders Program, previously told Being Patient
Long-Term Risks Still Unclear
The trials were 26 weeks long, and the report says that is not enough to determine whether Juvmo changes the risk of impulse-control problems. The available account also does not provide detailed rates of side effects, results broken down by patient group, or head-to-head comparisons with existing medicines. Those gaps limit conclusions about how its benefits and risks compare across treatment choices.
Although the report describes the standalone-trial side effects as mild to moderate, it does not include the full prescribing information or establish that Juvmo prevents dyskinesia or other complications. Patients and clinicians will need the product’s official safety information to understand its warnings and use. The longer-term experience after the medicine reaches patients is also not yet known.
U.S. Launch Expected in October
AbbVie expects Juvmo to become available in the United States in October 2026. The report does not give a specific launch day, price, insurance-coverage details or information about access programs. Those details may affect when and how patients can obtain the medicine.
Once it is on the market, clinicians and patients will be able to assess its role alongside established treatments, using the approved label and individual medical circumstances to guide decisions. Further evidence from longer-term use would help clarify safety questions, including the potential for impulse-control problems. The FDA approval itself confirms the permitted uses described above, but does not resolve those remaining questions.
Key Questions
What did the FDA approve?
The FDA approved Juvmo (tavapadon), an AbbVie once-daily pill, to treat Parkinson’s motor symptoms. It is approved as a standalone treatment in early disease and as an add-on to existing medicines in later stages.
When is Juvmo expected to be available?
AbbVie expects the medicine to be available in the United States in October 2026. The report does not provide a specific launch date.
How is Juvmo different from some existing Parkinson’s medicines?
According to the report, Juvmo targets D1 and D5 dopamine receptors, while commonly used dopamine agonists activate D2 and D3 receptors. It is also designed for once-daily use. These differences do not establish that it will have fewer side effects for every patient.
What benefits were reported in the trials?
Two 26-week trials of tavapadon on its own reported improvements in motor symptoms. A third trial found that add-on use helped extend “on time” and reduce “off time.” The source report describes nausea and headache among side effects in the standalone trials.
Does the evidence show whether Juvmo affects impulse-control problems?
No. The source report says the 26-week trials were not long enough to determine whether treatment changes the risk of impulse-control problems. That question remains unresolved.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
